sector medic suppli devic
downgrad neutral
messag ew share finish septemb strong back bullish tct
broader transcathet valv complex howev coapt also rais new question
ew mitral program view current level dont believ stock
bake potenti neg pipelin updat ew adjust post-coapt
world tail risk could aris upcom catalyst data tavr ncd
lotu launch meanwhil recent physician survey suggest limit upsid potenti
street expect result prefer move sidelin neutral
rate buy
edward big outperform large-cap med-tech last week vs
 one hand could argu
compani gain transcathet mitral valv market becom
realiti competitor cardiovascular space continu diversifi
recent year edward sharpen focu core compet structur
heart critic care result pipelin lean heavili mitral tricuspid
opportun drive next leg growth posit coapt result
develop tmvr market howev also think rais sever question
edward effort arena
first list whether edward activ cardioband trial complet
current form one lesson mitra-fr coapt patient
select trial design matter achiev stellar result coapt abbott went
gruel year process screen patient evalu
actual enrol studi result popul ideal suit demonstr
treatment effect mitraclip one patient suffer sever mr whose
left ventricl still healthi enough respond regurgit address
patient also max med minim nois associ
intra-tri rx chang come tct surpris mani compani
tmvr field reevalu trial design light find
beyond determin whether target right patient edward may also
grappl new enrol challeng heard sever physician
tct would consid uneth conduct anoth fmr trial random
medic manag given stark outcom dispar observ coapt
concern transcathet mitral valv replac studi conduct
use surgic control arm ew activ studi compar
cardioband medic manag tct analyst meet edward manag
team declin comment close studi complet enrol howev
could envis scenario recruit patient becom much challeng go
forward particularli mitraclip label expand
long-term coapt could also make mitraclip difficult incumb
displac view annuloplasti system like cardioband eventu
becom first-lin therapi within transcathet mitral valv repair segment
preserv futur treatment option like transcathet replac better leaflet
modif system compani posit first-to-market direct
annuloplasti system scenario would play edward strength coapt
howev sens talk clinician pendulum may swing
direct leaflet technolog tct analyst meet abbott also disclos
work new transcathet approach revis fail mitraclip could
increas appeal technolog edward pascal program could eventu
allow compet head-to-head mitraclip product behind cardioband
manag target ce mark approv expect edward provid
updat tmvr ttvr program analyst meet
page analyst certif import disclosur
meantim recent physician survey suggest limit upsid potenti
near-term street estim conduct survey high volum intervent
cardiologist group person perform tavr procedur roughli
total tavr volum repres center respons closer
domest market respond tavr volum sequenti
roughli line current consensu forecast call tavr
market grow quarter-over-quart revenu basi would low
end histor trend market averag sequenti gain
sinc sequenti growth also averag howev
worth note respond report sequenti increas center
volum consist gain report market overal
result take-away data point street expect like fair
head result similarli respond forecast volum growth
center line increas current assum consensu
forecast note outlook physician gener assum low risk
data schedul present march posit expect
outcom tavr roughli equival savr popul
figur respond tavr volum quarter
look ahead see sever potenti tail risk believ arent
reflect ew share current level least like materi
view neg surpris low risk trial see studi larg de-
risk least far primari endpoint concern drama head
seemingli strongli result trend favor tavr on-going
reconsider tavr ncd harder dismiss howev kol commun
continu split issu access vs qualiti care cardiovascular
profession societi advoc restrict minimum volum threshold
could theoret reduc number center certifi perform procedur
like chang would come grace period
hospit could work meet new requir believ shift could
meaning disrupt near-term decid implement societi
recommend decis memo agenc due march
page analyst certif import disclosur
final continu see downsid risk evolv tavr competit
landscap guid launch lotu edg believ
timelin could prove conserv fda alreadi review comment
first two modul lotu pma file prior boston submit final modul
given backdrop month turnaround time doesnt seem unrealist us
could pull potenti approv forward late much share boston
might take come market respond estim theyll shift
volum lotu compar favor model assum
boston captur share first full year market
figur project cep util tavr case
sentinel could also allow boston punch weight lotu roll
recent survey respond said expect util cerebr embol
protect least tavr case indic
plan use cep procedur cite new standard care
sens come tct consensu cep tavr shift
toward standard care camp especi follow cmss recent decis grant
sentinel cover cost filter went effect
mean sentinel potenti give boston seat tabl major
tavr case opportun compani tri leverag drive increas
lotu adopt long-term abbott also loom potenti fourth player
tavr market result portico studi set present solid
data could put portico track earli launch introduc new question
price dynam competit share intensifi
risk/reward longer favor move sidelin lower ew
estim modestli take account recent fx fluctuat latest tavr market
forecast model call adjust ep total
revenu organ project ep
cc sale stock trade revis ntm ep
estim prior price target longer view risk/reward
favor current level result downgrad ew share neutral
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track least doubl next five year edward pois primari
beneficiari growth even competit increas strong run year date
howev vs see posit long-term outlook larg
bake meanwhil competit tavr market set intensifi
potenti downsid risk cmss pend reconsider tavr ncd
reflect stock current level view result dont see
risk/reward favor
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat also make
compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv fair valu estim assum
wacc termin growth rate calcul forward npv per
share equat multipl forward ntm ep estim better
upsid opportun elsewher group view downgrad edward
neutral buy
upsid risk rate includ faster-than-expect tavr market growth
edward defend leadership posit world-wide tavr share better
forecast posit clinic and/or regulatori develop compani pipelin
transcathet mitral tricuspid technolog
downsid risk rate includ tavr market growth fall short street
expect greater-than-expect share gain new tavr competitor
come market clinic and/or regulatori setback pipelin program caus
investor question sustain edward premium growth profil
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
